APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
Thanks to its tissue-repairing effects, Bio'n improves the physiologic corneal healing process,
accelerating the healing rate. By reducing the formation of corneal scarring after a trauma and by
regulating the angiogenesis, Bio'n favors the re-establishment of the original corneal transparency.
Complete
Non confidential
Opportunity
Profile
> Improvement of corneal healing demonstrated in a rabbit pre-clinical model:
Bio'n induces a rapid and physiologic wound closure, with reduced corneal scarring and
angiogenesis.
